ALB and nephritis: Remission of nephritis occurred in 9 of 12 patients (75%) in the hUC-MSC group and 5 of 6 patients (83%) in the placebo group (no p value stated).A similar proportion of patients in each treatment arm achieved complete remission (no p value stated).Improvements in serum albumin, complement, renal function, SLEDAI, BILAG were similar in both groups (no p value stated).The trial was abandoned after 18 patients were enrolled, clear it would not demonstrate a positive treatment effect.